Stockscreener 앱 받기
2.01
4.15%
0.08
Inhibikase Therapeutics Inc 주식(IKT)의 최신 뉴스
How Inhibikase Therapeutics (IKT) is navigating logistics challenges | Q4 2025: EPS Tops ViewsPro Trader Recommendations - Newser
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
IKT Inhibikase Therapeutics beats Q4 2025 loss estimates, shares post modest gains following earnings release.Market Buzz Alerts - Newser
[DEF 14A] Inhibikase Therapeutics, Inc. Definitive Proxy Statement - Stock Titan
Is Inhibikase Therapeutics (IKT) stock reversing trend | Inhibikase Therapeutics notches 13.6% EPS beat on narrower lossEBITDA Margin - Newser
IKT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Inhibikase Therapeutics (IKT) asks shareholders to add 3M plan shares - Stock Titan
Inhibikase enrolls first patient in phase 3 PAH trial - MSN
Inhibikase Therapeutics (IKT) Stock Trading Today (+7.65%) 2026-04-18Crowd Consensus Signals - Cổng thông tin điện tử tỉnh Lào Cai
Inhibikase Therapeutics | SCHEDULE 13G/A: Others - Moomoo
Top Inhibikase Therapeutics (IKT) Competitors 2026 - MarketBeat
Inhibikase Enrolls First Patient in Phase 3 PAH Trial - MyChesCo
Inhibikase grants stock options to five new employees - MSN
What does insider activity suggest for Inhibikase Therapeutics (IKT) Stock | Price at $1.76, Up 3.53%Loss Prevention - Newser
First patient enrolled in Phase 3 trial of PAH treatment IKT-001 - Pulmonary Hypertension News
MACD Signal: What is the Moat Score of Inhibikase Therapeutics IncQuarterly Growth Report & Short-Term High Return Ideas - baoquankhu1.vn
IKT Stock Price, Quote & Chart | INHIBIKASE THERAPEUTICS INC (NASDAQ:IKT) - ChartMill
Inhibikase Grants Stock Options to Five New Employees - MyChesCo
H.C. Wainwright reiterates Inhibikase stock rating on trial progress By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Inhibikase stock rating on trial progress - Investing.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension - Sahm
Inhibikase Therapeutics Begins Enrollment for PAH Drug Trial - National Today
Inhibikase Therapeutics Enrolls First Patient in Global Phase 3 IMPROVE-PAH Study for Pulmonary Arterial Hypertension Treatment 1 - Minichart
Inhibikase enrolls first patient in Phase 3 PAH drug trial By Investing.com - Investing.com South Africa
Inhibikase Therapeutics (IKT) Begins Key Phase 3 Trial Enrollmen - GuruFocus
Inhibikase Therapeutics Enrolls First Patient In Phase 3 Trial For Pulmonary Arterial Hypertension - marketscreener.com
Inhibikase Begins Pivotal Phase 3 Trial in PAH - TipRanks
Inhibikase enrolls first patient in Phase 3 PAH drug trial - Investing.com
Inhibikase Announces First Patient Enrolled in Global Phase 3 IMPROVE-PAH Trial of IKT-001 - TradingView
First patient dosed in Inhibikase (IKT) global Phase 3 IMPROVE-PAH trial of IKT-001 - Stock Titan
Springer Publishing Company & Cashmere Announce Partnership to Bring Trusted Healthcare Education Content to AI Systems - Weekly Voice
Inhibikase Therapeutics Announces Enrollment of First - GlobeNewswire
Inhibikase grants stock options to new employees under inducement plan - MSN
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Inhibikase Grants Stock Options to New Employees Under Inducement Plan - MyChesCo
IKT Technical Analysis & Stock Price Forecast - Intellectia AI
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Inhibikase Therapeutics Announces Inducement Grants - National Today
Inhibikase Therapeutics Grants Inducement Shares to New Hires - National Today
IKT Stock Analysis: Inhibikase Therapeutics Inc 0.55% dip at $1.8, biotech performance review - Newser
HC Wainwright Has Optimistic Outlook of IKT Q1 Earnings - Defense World
Nocion Therapeutics Appoints Mark Iwicki To Board - citybiz
HC Wainwright Issues Positive Estimate for IKT Earnings - MarketBeat
Inhibikase Therapeutics (IKT) Receives a Buy from H.C. Wainwright - The Globe and Mail
1.77%
0.25%
자본화:
|
볼륨(24시간):